InMed Pharmaceuticals Inc.
INM
$2.76
$0.010.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -12.53% | -11.94% | 5.17% | 11.18% | 140.49% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -12.53% | -11.94% | 5.17% | 11.18% | 140.49% |
| Cost of Revenue | -2.79% | -7.60% | 20.92% | 27.97% | 51.56% |
| Gross Profit | -27.63% | -18.89% | -17.87% | -21.54% | 2,576.21% |
| SG&A Expenses | 1.33% | 1.43% | -3.79% | -10.21% | -8.93% |
| Depreciation & Amortization | -1.56% | 1.49% | 5.48% | 8.61% | 7.70% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.02% | 0.93% | -0.13% | 1.74% | -5.99% |
| Operating Income | -21.73% | -11.02% | 3.45% | 2.92% | 37.99% |
| Income Before Tax | -36.71% | -24.55% | 2.27% | 3.35% | 60.73% |
| Income Tax Expenses | 294.44% | 115.15% | 12.70% | -45.80% | -84.07% |
| Earnings from Continuing Operations | -36.79% | -24.60% | 2.26% | 3.42% | 60.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.79% | -24.60% | 2.26% | 3.42% | 60.75% |
| EBIT | -21.73% | -11.02% | 3.45% | 2.92% | 37.99% |
| EBITDA | -22.52% | -11.33% | 3.71% | 3.20% | 38.87% |
| EPS Basic | 49.85% | 57.65% | 70.48% | 76.57% | 93.09% |
| Normalized Basic EPS | 49.89% | 57.67% | 70.49% | 76.54% | 87.76% |
| EPS Diluted | 49.85% | 57.65% | 70.48% | 76.57% | 93.09% |
| Normalized Diluted EPS | 49.89% | 57.67% | 70.49% | 76.54% | 87.76% |
| Average Basic Shares Outstanding | 139.48% | 154.74% | 222.31% | 210.71% | 239.59% |
| Average Diluted Shares Outstanding | 139.48% | 154.74% | 222.31% | 210.71% | 239.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |